A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

A fresh crop of facelift patients is seeking beauty not youth—and redefining the century-old plastic surgery procedure in the ...

McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Whether it's weird workout classes or wild exercise devices, the rise of Ozempic is supercharging America's desire for ...

Ozempic (semaglutide) helps people with type 2 diabetes lower their blood sugar if diet, exercise, and other diabetes medications haven’t worked. If you’ve just gotten a prescription for it ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...